Login to Your Account

BioCryst Monetizes Peramivir Payments in $30M Financing

By Marie Powers

Friday, March 11, 2011
BioCryst Pharmaceuticals Inc. took an inventive tack to raise $30 million this week by monetizing payments from licensee Shionogi & Co. Ltd., of Osaka, Japan, for peramivir (Rapiacta), a neuraminidase inhibitor for the treatment of influenza.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription